Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2023 | JK06, a biparatopic ADC in preclinical development

Samuel Murphy • 17 Apr 2023
AACR 2023
General Antibodies JK06

Samuel Murphy, PhD, Salubris Bio, Gaithersburg, MD, provides an overview of JK06, a novel biparatopic antibody-drug conjugate (ADC). By targeting two different epitopes of the same antigen, delivery of the drug is enhanced and with a higher affinity for the antigen, lowly expressed antigens can additionally be targeted. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Samuel Murphy

2:42
JK08, a fusion protein of IL-15 and anti-CTLA-4 antibody, in solid tumors
Samuel Murphy • 17 Apr 2023

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals